Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma
Xoma的收入爲900萬美元,因爲美國食品藥品管理局加快批准了Ojemda(Tovorafenib)用於復發或難治性BRAF改變的兒科低級神經膠質瘤
Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma
Xoma的收入爲900萬美元,因爲美國食品藥品管理局加快批准了Ojemda(Tovorafenib)用於復發或難治性BRAF改變的兒科低級神經膠質瘤
使用瀏覽器的分享功能,分享給你的好友吧